---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-24-046314"
form_type: "8-K"
ticker: "GRCE"
cik: "0001444192"
company_name: "Grace Therapeutics, Inc."
filed_at: "2024-11-13T23:59:59+00:00"
generated_at: "2026-05-30T00:52:03.274359+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Grace Therapeutics reports Q2 net loss $3.4M; Phase 3 STRIVE-ON data due Q1 2025; cash into Q2 2026

## Summary
- Net loss of $3.4M ($0.30 per share) vs $3.3M ($0.43 per share) in prior year; R&D spend up to $3.0M on pivotal trial.
- Phase 3 STRIVE-ON safety trial enrollment complete; data readout expected Q1 2025; NDA submission for GTx-104 on track for 1H 2025.
- Cash and equivalents $15.1M; projected runway into Q2 2026.
- Redomiciled to Delaware and rebranded to Grace Therapeutics; ticker changed to GRCE on Nasdaq.
- Hosting KOL event on aSAH on Nov 20, 2024.

## SEC filing metadata
- accession: 0001140361-24-046314
- form_type: 8-K
- ticker: GRCE
- cik: 0001444192
- company_name: Grace Therapeutics, Inc.
- filed_at: 2024-11-13T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1444192/000114036124046314/0001140361-24-046314-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1444192/000114036124046314/ef20038398_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-24-046314
- JSON: https://secwatch.observer/filing/0001140361-24-046314.json
- Plain text: https://secwatch.observer/filing/0001140361-24-046314.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.